Moving Towards a Universal Vaccine Against Pneumonia and Meningitis
Scientists are actively researching a universal pneumococcal vaccine capable of targeting hundreds of Streptococcus pneumoniae serotypes, preventing severe conditions like pneumonia and meningitis. While current vaccines protect against specific serotypes, they leave gaps and can allow non-vaccine serotypes to proliferate. A recent British study demonstrated success using proteins instead of sugars to trigger broader immunity. Developing a universal vaccine remains challenging due to the large number of existing serotypes and the risk of serotype replacement, but it would eliminate the need for frequent reformulation and provide long-term protection.
Key Points
- Current pneumococcal vaccines only cover a limited number of the 100-odd existing serotypes.
- Researchers are exploring protein-based vaccines instead of traditional polysaccharide-based ones for broader protection.
- Universal vaccines could prevent serotype replacement and eliminate the need for frequent vaccine updates.
- Further clinical trials and human research are required to ensure safety and effectiveness.
Exam Facts
- Streptococcus pneumoniae is a bacterium that causes severe diseases like pneumonia, meningitis, and bloodstream infections.
- Current PCV vaccines include PCV10 and PCV14, denoting the number of serotypes included.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.